Immunome Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies for the treatment of various diseases. The company was founded in 2015 and is based in Exton, Pennsylvania. Immunome's mission is to leverage its proprietary antibody discovery platform to identify and develop novel antibody-based therapeutics that can address unmet medical needs.
The core focus of Immunome lies in the field of oncology and infectious diseases. The company utilizes its advanced technology platform to identify unique targets on cancer cells or infectious agents that can be targeted by therapeutic antibodies. By specifically binding to these targets, Immunome's antibodies have the potential to modulate the immune system's response and effectively combat the disease.
Immunome's proprietary platform combines high-throughput sequencing of patient-derived B cells with bioinformatics and functional screening to identify and isolate rare and potent antibodies. This approach allows for the identification of antibodies with high specificity and affinity, which are crucial for effective therapeutic intervention.
The company went public on February 5, 2021, with its initial public offering (IPO) on the NASDAQ stock exchange under the ticker symbol "IMNM." Going public provided Immunome with the necessary capital to support its research and development efforts, advance its antibody pipeline, and expand its capabilities.
Immunome is actively engaged in preclinical and clinical development of its antibody candidates. The company collaborates with pharmaceutical partners, academic institutions, and other organizations to further validate and advance its therapeutic candidates. The goal is to ultimately bring these antibody-based therapies to patients in need.
With its innovative approach to antibody discovery and development, Immunome aims to make a significant impact in the field of precision medicine. By harnessing the power of the immune system through targeted antibody therapies, Immunome strives to provide new treatment options for patients facing challenging diseases, contributing to the advancement of personalized medicine and improving patient outcomes.